PSMA Radioligand Plus Radiation Doubles Progression‑Free Time

UCLA researchers presented results at this week’s ASTRO meeting from a randomized trial testing the addition of a PSMA‑targeted radioligand (177Lu‑PNT2002) to stereotactic body radiation for men with limited (oligometastatic) recurrent prostate cancer. Ninety‑two men were randomized: those receiving the combination therapy had a median progression‑free interval of nearly 18 months versus about seven months with radiation alone, and the approach may delay the need for systemic hormone therapy. The drug is investigational and not yet FDA‑approved for this disease stage.